pranlukast

Pranlukast is a small molecule leukotriene receptor antagonist primarily used for the prevention and treatment of bronchial asthma and allergic rhinitis. It acts by selectively antagonizing the cysteinyl leukotriene receptor 1 (CysLT1), thereby inhibiting the action of leukotriene D4 (LTD4). This prevents airway edema, smooth muscle contraction, and excessive mucus secretion in response to allergens. Pranlukast is typically used as an adjunct to inhaled corticosteroids and beta agonists in asthma management. It was first developed by Ono Pharmaceutical in Japan, where it has been widely marketed since its approval in 1995[1][2][3][4][5].

Brand names

OnonAzlaire

Other names

Pranlukast hydrateN-[4-oxo-2-(2H-tetrazol–5–yl)chromen–8–yl]–4-(4–phenylbutoxy)benzamide